Progression-free survival
Fig 2 · Panel Progression-free_survival
Panel Progression-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Rui You, Gui-Qiong Xu, Xi Ding, Jin-Hui Liang, Zhi-Gang Liu, Xiong Zou, You-Ping Liu, Guang-Yuan Hu, Yi-Min Liu, Chong-Yang Duan, Li-Zhi Liu, Wei-Jing Zhang, Qian Liu, Hui-Feng Li, Yan-Feng Ouyang, Xiao-Tong Duan, Qin Wang, Lan Peng, Jiong-Lin Liang, Zheng-Kai Feng, Zi-Han Qin, Xiao Liu, Zhi-Kun He, Bin Zhang, Guo-Xian Long, Yan-Hui Jiang, Feng Lei, Pei-Yu Huang, Yi-Jun Hua, Ming-Yuan Chen
BMJ 392 e085863
OBJECTIVE: To assess treatment with camrelizumab (a programmed death 1 inhibitor) in addition to concurrent chemoradiotherapy and as a maintenance treatment in patients with high risk nasopharyngeal carcinoma. DESIGN: Multicentre, randomised, open label, phase 3 trial. SETTING: Seven hospitals in China between 18 August 2020 and 21 June 2022. PARTICIPANTS: Adults aged 18-70 years with newly diagnosed high risk nasopharyngeal carcinoma after three cycles of induction chemotherapy with gemcitabine and cisplatin (stage 4a, stage 2-3 with stable or progressive disease, or detectable Epstein-Barr virus DNA). INTERVENTIONS: Patients were randomly assigned (1:1) to receive combination chemoradiotherapy based on cisplatin (standard treatment group) or standard treatment with 19 cycles of intravenous camrelizumab (200 mg) once every three weeks (radiotherapy plus two concurrent cycles and 17 adjuvant cycles; camrelizumab group). MAIN OUTCOME MEASURES: The primary endpoint in the intention-to-treat group was progression-free survival, defined as the time from randomisation to disease recurrence (locoregional or distant) or death from any cause. Secondary endpoints included safety and overall survival. RESULTS: 390 patients were enrolled and randomly assigned to the camrelizumab group (n=194) or the standard treatment group (n=196). At median follow-up of 39.9 months (interquartile range 36.8-43.4 months), progression-free survival was higher in the camrelizumab group than the standard treatment group (36 months: 83.4%, 95% confidence interval 78.3% to 88.8% v 71.3%, 65.2% to 77.9%; stratified hazard ratio 0.51, 95% confidence interval 0.34 to 0.77, P=0.001). The incidence of acute and late adverse events (grade 3 or 4) was 50.5% and 3.2% in the camrelizumab group compared with 48.7% and 3.7% in the standard treatment group. Immunological adverse events (grade 3 or 4) occurred in 19 patients (10.2%) in the camrelizumab group. CONCLUSION: The addition of camrelizumab to concurrent chemoradiotherapy and as a maintenance treatment improved progression-free survival among patients with high risk nasopharyngeal carcinoma after induction chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04453826.
1 个 Figure · 4 个 KM 面板
Fig 2 Kaplan-Meier survival analysis of intention-to-treat population at 36 months
Fig 2 · Panel Progression-free_survival
Panel Progression-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 2 · Panel Distant_metastasis-free_survival
Panel Distant_metastasis-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 2 · Panel Locoregional_recurrence-free_survival
Panel Locoregional_recurrence-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 2 · Panel Overall_survival
Panel Overall_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。